Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.58 |
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14559793 | 1.00 | CASP3 (0.58) | CASP3MDM4TP53MDM2TLR2 | |
| SCHEMBL12138344 | 1.00 | CASP3 (0.58) | CASP3MDM4TP53MDM2TLR2 | |
| SCHEMBL13256282 | 0.91 | CASP3 (0.54) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL14586400 | 0.91 | CASP3 (0.54) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13382807 | 0.91 | CASP3 (0.54) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL25173084 | 0.90 | CASP3 (0.56) | CASP3MDM4TP53MDM2TLR2 | |
| SCHEMBL14570616 | 0.90 | CASP3 (0.56) | CASP3MDM4TP53MDM2TLR2 | |
| SCHEMBL800126 | 0.90 | CASP3 (0.56) | CASP3MDM4TP53MDM2TLR2 | |
| SCHEMBL1486199 | 0.90 | CASP3 (0.64) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL378040 | 0.90 | CASP3 (0.64) | CASP3MDM4TP53MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9096642-B2 | Therapeutic compounds for immunomodulation | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-08-04 | — | — | US | disclosed |
| US-9045507-B2 | Coumarin-based amino acids for use in enzyme activity and substrate specificity assays | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20140199334-A1 | Therapeutic Compounds for Immunomodulation | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-17 | — | — | US | disclosed |
| US-20100086957-A1 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-04-08 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7193034-B2 | Synthetic peptides, conjugation reagents and methods | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-20 | — | — | US | disclosed |
| US-7193034-B2 | Synthetic peptides, conjugation reagents and methods | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070031892-A1 | Novel coumarin-based amino acids for use in enzyme activity and substrate specificity assays | USC | 2007-02-08 | — | — | US | disclosed |
| US-20060035305-A1 | Synthetic peptides, conjugation reagents and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-02-16 | — | — | US | disclosed |
| US-6939945-B2 | Synthetic peptides, conjugation reagents and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-06 | — | — | US | disclosed |
| US-20030073157-A1 | Synthetic peptides, conjugation reagents and methods | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-04-17 | — | — | US | disclosed |
| US-6465612-B1 | A PEPTIDE CONTAINING A (2S)-AMINOLEVULINIC ACID RESIDUE WITH SUBSTITUTED OR UNSUBSTITUTED KETONE GROUP | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | CASP3 513/4885MDM4 4381/4885TP53 3992/4885 |
| US-20100086957-A1 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | PTPRCAP, PTPRC, PTPA | CASP3 3800/4885MDM4 1983/4885TP53 587/4885 |
| US-20060035305-A1 | Synthetic peptides, conjugation reagents and methods | PTMS, QPCT, LNPEP | CASP3 3160/4885MDM4 1134/4885TP53 1147/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | CASP3 2917/4885MDM4 702/4885TP53 175/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | CASP3 3107/4885MDM4 1478/4885TP53 215/4885 |
| US-20140199334-A1 | Therapeutic Compounds for Immunomodulation | CD274, PDCD1, PDCD1LG2 | CASP3 948/4885MDM4 660/4885TP53 44/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CASP3 3488/4885MDM4 471/4885TP53 196/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CASP3 3488/4885MDM4 471/4885TP53 196/4885 |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | CD274, PDCD1, PDCD1LG2 | CASP3 730/4885MDM4 438/4885TP53 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.